SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 24th, 2000 • Keryx Biophamaeuticals Inc • Services-commercial physical & biological research • New York
Scientific Advisory Board AgreementScientific Advisory Board Agreement • September 15th, 2023 • Acesis Holdings Corp. • Biological products, (no disgnostic substances) • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as January 1, 2023 (the “Effective Date”), and is entered into by Acesis Biomed US, Inc., with a business address at 9233 Park Meadows Drive Suite 108, Lone Tree, Colorado 80124, USA (the “Company”), and Dr. Ravi Kacker with a business address at 67 Union St #308, Natick, Massachusetts 01760 (the “Advisor”). This Agreement shall replace and supersede any and all previous written agreements between the Company and Advisor regarding Scientific Advisory Board Services.
RXI PHARMACEUTICALS CORPORATION SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • January 10th, 2008 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Scientific Advisory Board Agreement (the “Agreement”) dated as of February 26, 2007, is made by Michael P. Czech, Ph.D. (the “SAB Member”) and RXi Pharmaceuticals Corporation, a Delaware corporation (“RXi” and together with the SAB Member, the “Parties”). The SAB Member is a faculty member at the University of Massachusetts.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 5th, 2010 • Medgenics, Inc. • New York
THIS AGREEMENT (the “Agreement”) dated as of 22 October 2008 (“Effective Date”) is made by and between Medgenics, Inc. located at 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182, USA (the “Company”); and
Scientific Advisory Board AgreementScientific Advisory Board Agreement • March 7th, 2018 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of March 1, 2018 (the “Effective Date”), and is entered into by IASO BioMed Inc., with a business address at 7315 East Peakview Ave., Centennial, CO 80111, USA (the “Company”), and Dr. Costas Karatzas personally or through CNKonsulting with a business address at _____________________________ (the “Advisor”).
STOKE THERAPEUTICS, INC. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • August 8th, 2022 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This SCIENTIFIC ADVISORY BOARD Agreement (this “Agreement”) is entered into as of June 1, 2022 (the “Effective Date”) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (“Stoke”) and Adrian Krainer, Ph.D. (“Advisor”). Advisor has unique skills and knowledge pertinent to Stoke’s business and Stoke desires to retain Advisor as a member of Stoke’s Scientific Advisory Board (“SAB”) under the terms of this Agreement.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • June 10th, 2015 • E-Qure Corp. • Wholesale-misc durable goods • California
THIS ADVISORY BOARD AGREEMENT is made effective as of January 1, 2015, (the "Effective Date") by and between E-QURE Corp, a (the "Company"), and Dr. Ben Zion Weiner (the "Advisor").
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 11th, 2011 • Stem Cell Assurance, Inc. • Services-misc health & allied services, nec • Florida
SCIENTIFIC ADVISORY BOARD AGREEMENT, dated as of June 10, 2011, by and between NAIYER IMAM, M.D. (the “Advisor”), having an address at 6185 Steeplechase Drive, Roanoke, Virginia, and STEM CELL ASSURANCE, INC., a Nevada corporation (the “Company”), having offices at 555 Heritage Drive, Suite 130, Jupiter, Florida 33458.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California
This Scientific Advisory Board Agreement (“Agreement”), effective as of June 18, 2012 (“Effective Date”), is made between Caribou Biosciences, Inc. (“Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”) (each may be referred to below individually as a “party” and collectively as the “parties”).
Amendment No. 5 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 5 to Scientific Advisory Board Agreement (“Amendment No. 5”), effective January 1, 2020 (“Amendment No. 5 Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016, Amendment No. 3 to Scientific Advisory Board Agreement, dated January 1, 2017, and Amendment No. 4 to Scientific Advisory Board Agreement, dated March 31, 2018 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used in this Amendment No. 5 that is not defined herein has the meaning ascribed to it in the Agreement.
Amendment No. 3 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3, effective January 1, 2017 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, and Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined has the meaning ascribed to it in the SAB Agreement.
Amendment No. 2 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2, effective May 31, 2016 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated April 12, 2014 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation having its address at 2929 7th Street, Suite 105, Berkeley, CA 94710, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined shall have the meaning ascribed to it in the SAB Agreement.
ENDOCARE, INC.Scientific Advisory Board Agreement • September 20th, 2001 • Endocare Inc • Electromedical & electrotherapeutic apparatus • California
ERASCA, INC. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • June 25th, 2021 • Erasca, Inc. • Pharmaceutical preparations • California
THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2020 (the “Effective Date”), by and between ERASCA, INC., a Delaware corporation (the “Company”), having its principal place of business at 10835 Road to the Cure, Suite 140, San Diego, CA 92121, and MICHAEL D. VARNEY, PH.D., an individual with an address at 709 N. Granados Ave., Solana Beach, CA 92075 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
Amendment No. 4 to Scientific Advisory Board AgreementScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 4, effective March 31, 2018 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016, and Amendment No. 3 to Scientific Advisory Board Agreement, dated January 1, 2017 (“Amendment No. 3”) (and collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined has the meaning ascribed to it in the SAB Agreement.
AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California
This Amendment No. 1 (“Amendment No. 1”) to the Scientific Advisory Board Agreement dated June 18, 2012 (the “Agreement”), by and between Jennifer A. Doudna (“Advisor”), an individual, and Caribou Biosciences, Inc., a Delaware corporation, having its principal place of business at 2929 7th Street Suite 120, Berkeley, CA 94710 (“Caribou”) (Advisor and Caribou collectively referred to hereinafter as the “Parties”), is entered into as of April 12, 2014 (the “Amendment No. 1 Execution Date”).
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • February 16th, 2010 • Lifevantage Corp • Pharmaceutical preparations • California
This Scientific Advisory Board Agreement (“Agreement”) is by and between Joe McCord, M.D., (“Consultant”) and LifeVantage Corporation (the “Company”), effective as of October 1, 2009, the (“Effective Date”). Company and Consultant may be referred to herein individually as a “Party” and together as the “Parties.”
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 5th, 2010 • Medgenics, Inc. • New York
THIS AGREEMENT (the “Agreement”) dated as of May 1 2006 (“Effective Date”) is made by and between Medgenics, Inc. located at of 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182. USA (the “Company”); and
AMENDMENT OF SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • September 28th, 2011 • Lifevantage Corp • Pharmaceutical preparations
This Amendment of the Scientific Advisory Board Agreement (“Amendment”) is made and entered into as of July 21, 2011 (“Execution Date”) by and between Dr. Joe M. McCord, Ph.D., (“Consultant”) and LifeVantage Corporation, a Colorado Corporation (the “Company”).
FORM OF SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • May 14th, 2007 • Modigene Inc. • Services-mailing, reproduction, commercial art & photography • New York
This Agreement is made as of _____________ ___, 2005, between Modigene Inc. (the "Company"), and ____________________ (the "Consultant"'), and shall be effective as of the date this Agreement has been approved by the Board of Directors of the Company (the "Effective Date"). Consultant has been involved in fields of particular interest to the Company. The Company wishes to retain Consultant in a consulting capacity as a member of the Company's Scientific Advisory Board (the "SAB"), and Consultant desires to perform such consulting services. Accordingly, the parties agree as follows:
VITAL LIVING, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT This Scientific Advisory Board Agreement ("Agreement") dated June 17, 2002, (the "Effective Date") is made by and between Vital Living, Inc., a Nevada corporation, whose address is 2800 S. Rural...Scientific Advisory Board Agreement • July 2nd, 2002 • Vital Living Inc • Pharmaceutical preparations • California
INVIVO THERAPEUTICS CORPORATION SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 1st, 2010 • Invivo Therapeutics Holdings Corp. • Wholesale-furniture & home furnishings • Massachusetts
This Scientific Advisory Board Agreement (this “Agreement”) between [insert name], having an address at [insert address] (the “Member”), and InVivo Therapeutics Corporation, (the “Company”), a Delaware corporation having a principal place of business at One Broadway 14th Floor, Cambridge, MA 02142, is made effective as of September 25, 2008 (the “Effective Date”). In connection with the appointment of the Member to the Advisory Board (the “SAB”) of the Company and the mutual promises of the parties hereunder, it is agreed as follows:
Scientific Advisory Board AgreementScientific Advisory Board Agreement • September 15th, 2023 • Acesis Holdings Corp. • Biological products, (no disgnostic substances) • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of January 1, 2023 (the “Effective Date”), and is entered into by Acesis Biomed US, Inc., with a business address at 9233 Park Meadows Drive - Suite 108, Lone Tree, Colorado 80124, USA (the “Company”), and Peter Yiwen Liu, MD, PhD with a business address 1124 W Carson St Bldg RB1, Torrance, California 90502 (the “Advisor”). This Agreement shall replace and supersede any and all previous written agreements between the Company and Advisor regarding Scientific Advisory Board Services.
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • March 21st, 2014 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Arizona
THIS AGREEMENT (the “Agreement”) is made and entered into this 24th day of December, 2013 (the “Effective Date”) between Lixte Biotechnology Holdings, Inc., 248 Route 25A No. 2, East Setauket, New York 11733 (hereinafter referred to as the “Company”), and NDA Consulting Corp., an Arizona corporation, with offices at 9977 N. 90th Street, Suite 175, Scottsdale, Arizona 85258 (hereinafter referred to as the “Consultant”).
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 25th, 2006 • Kosan Biosciences Inc • Services-commercial physical & biological research • California
THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Agreement”) is made and entered into as of July 19, 2006 (the “Effective Date”), by and between KOSAN BIOSCIENCES INCORPORATED, a Delaware corporation with a place of business at 3832 Bay Center Place, Hayward, CA 94545 (the “Company”), and CHAITAN S. KHOSLA, PH.D., an individual with an address at 740 La Para Avenue, Palo Alto, CA 94306 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as “Parties.”
RXI PHARMACEUTICALS CORPORATION SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • January 10th, 2008 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Scientific Advisory Board Agreement (the “Agreement”) dated as of February 26, 2007, is made by Gregory J. Hannon, Ph.D. (the “SAB Member”) and RXi Pharmaceuticals Corporation, a Delaware corporation (“RXi” and together with the SAB Member, the “Parties”). The SAB Member is an investigator of the Howard Hughes Medical Institute (the “Institute”) at the Institute’s laboratory at Cold Spring Harbor Laboratory.
SENTI BIOSCIENCES, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Agreement”) is made and entered into as of May 14, 2021 (the “Effective Date”), by and between SENTI BIOSCIENCES, INC., a Delaware corporation...Scientific Advisory Board Agreement • March 22nd, 2023 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances) • California
As part of its ongoing program of research and development, the Company desires to retain distinguished scientists and other qualified individuals to advise the Company with respect to its technology strategy and to assist it in the research, development and analysis of the Company’s technology. In furtherance thereof, the Company desires to retain Advisor as a consultant and member of the Company’s Scientific Advisory Board, and the Company and Advisor desire to enter into this Agreement.
QUANTUMSCAPE BATTERY, INC. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • July 29th, 2022 • QuantumScape Corp • Miscellaneous electrical machinery, equipment & supplies • California
This Scientific Advisory Board Agreement (this “Agreement”) is effective as of June 6, 2022 (the “Effective Date”) by and between QuantumScape Battery, Inc. (the “Company”) and Celina Mikolajczak (“Advisor”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). For the purposes of this Agreement, the Company’s publicly listed parent corporation, QuantumScape Corporation, is referred to as “QuantumScape.”
EXHIBIT 10.9 SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • March 28th, 1996 • Incstar Corp • In vitro & in vivo diagnostic substances • Minnesota
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • November 5th, 2010 • Medgenics, Inc. • New York
THIS AGREEMENT (the “Agreement”) dated as of May 1 2006 (“Effective Date”) is made by and between Medgenics, Inc. located at of 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182. USA
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • March 19th, 2020 • Moleculin Biotech, Inc. • Pharmaceutical preparations • Texas
This Scientific Advisory Board Agreement (the “Agreement”) is entered into as of the 28th day of February, 2020, by and between Moleculin Biotech, Inc. (the “Company”) and Waldemar Priebe, PhD (the “Science Advisor”).
SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • August 4th, 2009 • Proteonomix, Inc. • New York
THIS AGREEMENT (this "Agreement") is made and entered into as of June 2, 2008 (the "Effective Date"), by and between National Stem Cell Holding, Inc., a Delaware corporation having an address at Mountainside, N7 07092 (the “Company"), and Barbara Nabrit Stephens, M.D., with an address at 4704 Dunnie Drive, Tampa, Florida 33614 (the "Member"). The parties to this Agreement are hereinafter referred to as the “Parties.”
Scientific Advisory Board AgreementScientific Advisory Board Agreement • May 6th, 2019 • Bioxytran, Inc • Pharmaceutical preparations • Massachusetts
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of May 1st, 2019 (the “Effective Date”), and is entered into by Bioxytran, Inc., with a business address at 233 Needham St., Suite 300, Newton, MA 02464 (the “Company”), and Juan Carlos Lopez-Talavera (the “Advisor”) through Asclepius LLC with a business address 14 Hampton Drive Woodbridge, CT 06525 (the “Advisor”).
AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • September 23rd, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Amendment”), is dated as of September 21, 2016, by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (with its subsidiaries, the “Company”), and Barry Buckland, Ph.D. (the “Advisor”). This Amendment amends that certain Scientific Advisory Board Agreement, dated as of September 14, 2014, by and between the Company and the Advisor (the “SAB Agreement”). Capitalized words used but not otherwise defined herein shall have the meanings ascribed to such terms in the SAB Agreement.
PLX PHARMA INC. SCIENTIFIC ADVISORY BOARD AGREEMENTScientific Advisory Board Agreement • October 5th, 2015 • PLX Pharma Inc. • Pharmaceutical preparations • Texas
This SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Agreement”), made this __ day of ___, 2015, is entered into by PLx Pharma Inc., a Delaware corporation (the “Company”), and ______________________ an individual (the “Advisor”).
